Family's $2M Campaign Sparks FDA Gene Therapy Approval

When Cara and Glenn O'Neill learned their three-year-old daughter Eliza had a rare genetic disease, they chose action over despair. Their fierce devotion has now transformed modern medicine for children around the world.

In 2013, doctors diagnosed Eliza with Sanfilippo syndrome, a rare condition that progressively limits speech, movement, and overall development. At the time, no approved treatments existed, leaving families with few options and little hope.

Across the country at Nationwide Children's Hospital in Ohio, researcher Haiyan Fu had spent years developing an innovative gene therapy for the condition. Funding shortages nearly halted her laboratory research, but determined patient families stepped forward to keep her vital work alive.

Committed to funding the first human clinical trials, the O'Neills partnered with a filmmaker to share Eliza's journey online. Their 2014 video captured hearts across the globe, raising over two million dollars and setting crowdfunding records.

Thanks to that massive wave of public generosity, clinical trials officially began in 2016, with Eliza becoming the first patient to receive the experimental treatment. The therapy uses a harmless, modified virus to deliver working copies of the missing gene directly into cells.

The remarkable clinical trial results caught the attention of biotech company Ultragenyx, which guided the therapy through final development. The Food and Drug Administration recently approved the treatment, now called Fayuvi, marking an extraordinary victory for rare disease research.

The Ripple Effect

A grassroots effort by loving parents created a ripple of hope that now spans the entire medical landscape. The treatment offers its strongest benefits when administered to newly diagnosed infants, giving young children the opportunity to maintain vital brain function and thrive.

Beyond this single breakthrough, the milestone proves that everyday families can reshape scientific history through collective action. Biotech leaders and research institutions are now partnering directly with patient foundations, accelerating life-saving solutions for countless other rare conditions.

Because one family chose to believe in the impossible, children everywhere now have a genuine chance at a long, healthy future.